Vitiligo in a patient receiving infliximab for chronic plaque psoriasis.

Infliximab is a tumor necrosis factor-alpha (TNF-a) inhibitor widely used in the treatment of moderate to severe chronic plaque psoriasis. Here, we report a case of vitiligo following infliximab administration in a patient with chronic plaque psoriasis. The case serves as a reminder of vitiligo induced by TNF-a-antagonist therapy.